Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Determination of Enzyme Inhibition in SARS-CoV-2 3-Chymotrypsin-Like Protease (3CLP) Assay from US Patent US20230399296: "RNA VIRUS INHIBITOR COMPOUNDS WITH IMPROVED METABOLIC STABILITY AND USES THEREOF"
Assay data:7 Active, 7 Activity ≤ 1 µM, 7 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Fluorescence Mpro inhibition assay (S2) from Article : "Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors."
Assay data:244 Active, 131 Activity ≤ 1 µM, 381 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Target
Fluorescence Mpro inhibition assay (S1) from Article : "Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors."
Assay data:924 Active, 1 Activity ≤ 1 nM, 476 Activity ≤ 1 µM, 1933 Tested
Amide Coupling from Article : "Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors."
Assay data:32 Active, 32 Activity ≤ 1 µM, 32 Tested
Chan-Lam from Article : "Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors."
Assay data:296 Active, 5 Activity ≤ 1 µM, 296 Tested
SARS-CoV-2 Omicron Mpro Inhibition Assay from US Patent US11753373: "Protease inhibitors as antivirals"
Assay data:9 Active, 9 Activity ≤ 1 µM, 9 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Wild Type SARS-CoV-2 Mpro Inhibition Assay from US Patent US11753373: "Protease inhibitors as antivirals"
Assay data:46 Active, 45 Activity ≤ 1 µM, 55 Tested
3CLpro Inhibitory Activity Test from US Patent US11612603: "3-triazolyl methyl-1,3,5-triazine-2,4-dione compounds and preparation method and application thereof"
Assay data:22 Active, 24 Activity ≤ 1 µM, 24 Tested
Evaluation of STK19 Kinase Inhibitory Activity from US Patent US11542240: "STK19 inhibitors for treatment of cancer"
Assay data:17 Active, 17 Activity ≤ 1 µM, 17 Tested
3CLpro Inhibitory Activity Test from US Patent US11530195: "Protacs targeting coronavirus 3CL protease and preparation method and application thereof"
Enzymatic Assay from US Patent US11524940: "Inhibitors of cysteine proteases and methods of use thereof"
Assay data:223 Active, 310 Tested
SummaryCompounds, ActiveRelated BioAssays by Target
3CLpro Inhibitory Activity Assay from US Patent US11518759: "Protacs based on VHL ligand targeting coronavirus 3CL protease and preparation method and application thereof"
Enzyme inhibition assay and Ki values determination from WIPO Patent WO2023004291: "CORONAVIRUS MAIN PROTEASE INHIBITORS AND METHODS USING SAME"
Assay data:9 Active, 9 Activity ≤ 1 µM, 10 Tested
Rapid-Fire MS Biochemical Assay measuring Mpro activity (5nM Mpro) from WIPO Patent WO2022224223: "COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES"
Assay data:19 Active, 17 Activity ≤ 1 µM, 22 Tested
Rapid-Fire MS Biochemical Assay measuring Mpro activity (12.5nM Mpro) from WIPO Patent WO2022224223: "COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES"
Assay data:15 Active, 11 Activity ≤ 1 µM, 15 Tested
Antiviral activity from SARS-CoV-2 infection from WIPO Patent WO2022208262: "ETHER-LINKED ANTIVIRAL COMPOUNDS"
Assay data:25 Active, 2 Activity ≤ 1 nM, 25 Activity ≤ 1 µM, 25 Tested
Inhibition of SARS-CoV-2 3CLpro using FAM-SAVLQ/SG-QXL520 as substrate measured after 1 hr by fluorescence based microplate reader analysis
Assay data:30 Active, 27 Activity ≤ 1 µM, 30 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of N-terminal His6-tagged SARS-CoV2 Wuhan-Hu-1 3C-like protease infected in expressed in Escherichia coli BL21 (DE3) cells using FAM-SAVLQ/SG-QXL520 as substrate by FRET enzyme assay
Assay data:37 Active, 27 Activity ≤ 1 µM, 37 Tested
Inhibition of recombinant SARS-CoV-2 Main protease at Cys145 residue by non-covalent binding incubated for 45 mins by MS analysis
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of recombinant SARS-CoV-2 Main protease at Cys145 residue by covalent modification at 33 uM and measured after 60 mins in presence of TPCK by MS analysis
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on